RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-4.3%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$4.4B
AUM Growth
+$4.4B
(-23%)
Cap. Flow
-$286M
Cap. Flow
% of AUM
-6.51%
Top 10 Holdings %
Top 10 Hldgs %
53.32%
Holding
82
New
7
Increased
5
Reduced
49
Closed
11
Top Buys
| 1 |
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
|
$247M |
| 2 |
AUGX
Augmedix, Inc. Common Stock
AUGX
|
$45.3M |
| 3 |
Entrada Therapeutics
TRDA
|
$33.5M |
| 4 |
Centene
CNC
|
$29.8M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$25.1M |
Top Sells
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$97.2M |
| 2 |
argenx
ARGX
|
$73.2M |
| 3 |
The Beauty Health Co
SKIN
|
$58M |
| 4 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
$34M |
| 5 |
Celldex Therapeutics
CLDX
|
$33.9M |
Sector Composition
| 1 | Healthcare | 94.86% |
| 2 | Consumer Staples | 2.79% |
| 3 | Industrials | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Fate Therapeutics
FATE
$120M
| $758M | 17.24% | 12,957,222 | – | – |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $262M | 5.96% | 22,716,086 +1,916,783 | +9% | +$22.1M |
|
|
SNCE
3
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $247M | 5.62% | +19,808,234 | New | +$247M |
|
|
4
argenx
ARGX
$43.6B
| $183M | 4.15% | 521,643 -208,939 | -29% | -$73.2M |
|
5
LivaNova
LIVN
$3.08B
| $180M | 4.09% | 2,057,178 -133,841 | -6% | -$11.7M |
|
6
Kymera Therapeutics
KYMR
$2.95B
| $164M | 3.74% | 2,587,730 -205,978 | -7% | -$13.1M |
|
7
ADC Therapeutics
ADCT
$345M
| $151M | 3.42% | 7,451,029 -78,300 | -1% | -$1.58M |
|
8
Beam Therapeutics
BEAM
$1.66B
| $150M | 3.42% | 1,885,850 -89,156 | -5% | -$7.1M |
|
9
Krystal Biotech
KRYS
$4.27B
| $127M | 2.9% | 1,820,898 -161,534 | -8% | -$11.3M |
|
|
10
The Beauty Health Co
SKIN
$264M
| $123M | 2.79% | 5,082,805 -2,400,901 | -32% | -$58M |
|
11
Replimune Group
REPL
$422M
| $105M | 2.38% | 3,866,512 -211,600 | -5% | -$5.73M |
|
12
Atara Biotherapeutics
ATRA
$84.6M
| $101M | 2.31% | 6,437,777 -28,500 | -0.4% | -$449K |
|
|
IGMS
13
DELISTED
IGM Biosciences
IGMS
| $97.8M | 2.22% | 3,334,355 -91,100 | -3% | -$2.67M |
|
14
Nurix Therapeutics
NRIX
$714M
| $85.6M | 1.95% | 2,958,284 -134,793 | -4% | -$3.9M |
|
|
15
Celldex Therapeutics
CLDX
$1.47B
| $83.7M | 1.9% | 2,165,586 -877,712 | -29% | -$33.9M |
|
16
Absci
ABSI
$357M
| $65.9M | 1.5% | 8,031,094 | – | – |
|
|
VERV
17
DELISTED
Verve Therapeutics
VERV
| $63M | 1.43% | 1,708,536 -160,494 | -9% | -$5.92M |
|
18
Regenxbio
RGNX
$451M
| $62M | 1.41% | 1,897,223 -110,778 | -6% | -$3.62M |
|
|
IMGN
19
DELISTED
Immunogen Inc
IMGN
| $61.3M | 1.39% | 8,258,345 | – | – |
|
20
Scholar Rock
SRRK
$3.14B
| $60.8M | 1.38% | 2,447,926 -102,279 | -4% | -$2.54M |
|
21
Repare Therapeutics
RPTX
$71.7M
| $58.8M | 1.34% | 2,789,496 +221,800 | +9% | +$4.68M |
|
|
NVTA
22
DELISTED
Invitae Corporation
NVTA
| $58.1M | 1.32% | 3,805,403 -1,512,074 | -28% | -$23.1M |
|
|
SGEN
23
DELISTED
Seagen Inc. Common Stock
SGEN
| $57.5M | 1.31% | 371,839 -215,535 | -37% | -$33.3M |
|
24
Stoke Therapeutics
STOK
$1.08B
| $53.9M | 1.23% | 2,246,668 -135,290 | -6% | -$3.25M |
|
25
UnitedHealth
UNH
$281B
| $52.5M | 1.19% | 104,488 -16,222 | -13% | -$8.15M |
|